Newborns with heart complications can rely on their immune systems to regenerate, but adults aren’t so lucky. A new study explores this mechanism, paving the way for treatments after a heart attack.
Researchers have developed a new kind of tumour-on-a-chip, which gives insight into the tumour environment and immunotherapy response. The device has been successfully tested on breast cancer samples.
Persister cells arise as a result of cancer treatment and are often responsible for tumour relapse. Researchers identified a distinctive feature of persister cells, paving the way for new treatments.
The immune system of children reacts differently to cancer than that of adults. New insights into these differences have the potential to lead to new tailored treatments for children with cancer.
A new study measured how well breast cancer patients’ tumour ‘explants’ respond to chemotherapy or HER2 antibody therapy in the laboratory. This could help improve clinical outcomes.
Researchers have developed an AI-based model to better predict whether cancer patients will benefit from immunotherapy — using only routine blood tests and clinical data.
A molecule called MR1 (MHC Class I-related Molecule 1) enables a newly-discovered type of T-cells to sense differences in the metabolism that occur when cells become cancerous.
Researchers now succeeded in making leukemia-specific immune cells less sensitive to the influence of tumor cells, thereby significantly increasing their effectiveness.
Research offers new insights into harnessing the immune system to combat ovarian cancer. The findings could lead to personalized therapies that target the right patients at the right time.
New insights into the previously unknown diversity of cancer-associated fibroblasts in basal cell carcinoma, squamous cell carcinoma and melanoma could pave the way for new therapies.
PET/CT image analysis using artificial intelligence (AI) can predict the occurrence of interstitial lung disease, a serious side effect of immunotherapy in lung cancer, a new study shows.
Immunotherapy has become the most promising strategy for treating several cancers, but its effectiveness is still very uneven. Three researchers explain how research is being done to change this.
Scientists at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have developed CAR-T cells capable of targeting malignant gliomas while preserving healthy tissue.
STAb-T, a new form of immunotherapy to treat solid tumours shows therapeutic potential in animal models with non-small cell lung cancer. The new strategy is designed to strengthen the defensive cells.
Only 20-40% of patients respond positively to immunotherapy, and these rates vary across different types of cancer. Researchers now identified five key factors that determine response and survival.
Currently, it is difficult to predict whether a cancer patient will respond to immunotherapy or not. A new method to quantify the heterogeneity of the tumour microenvironment aims to improve this.
Immunocompromised patients are at greatest risk of developing severe Covid-19 after an infection. While early antiviral treatments yield best results, even late-onset therapies still show benefits.
Brazilian researchers have identified a key mechanism of Sars-CoV-2 to manipulate its host’s immune defense. This discovery could pave the way for the development of novel therapies.
Systemic lupus erythematodes can lead to severe kidney damage. However, until now, the cause for this remained unclear. New research has now revealed the underlying mechanism.
